REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
| Autor: | Nishio, Makoto, Yu, Helena Alexandra, Besse, Benjamin, Cheng, Ying, Tan, Daniel Shao-Weng, Wei, Li, Wacheck, Volker, Heymach, John |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement, Vol. 42, pTPS219-TPS219, 24p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|